路透7月16日 - 礼来公司(Eli Lilly, LLY.N)周四表示,将以最高38亿美元的价格收购迷幻药物开发商AtaiBeckley(ATAI.O),从而加入开发用于治疗抑郁症及其他精神健康障碍的迷幻疗法的竞争。
路透7月16日 - 礼来公司(Eli Lilly, LLY.N)周四表示,将以最高38亿美元的价格收购迷幻药物开发商AtaiBeckley(ATAI.O),从而加入开发用于治疗抑郁症及其他精神健康障碍的迷幻疗法的竞争。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.